High-Dose Aflibercept Sustains Outcomes Over 96 Weeks

The recently approved 8-mg dose of aflibercept has shown sustained improvement in vision and anatomical markers out to 96 weeks, according to updated clinical trial results.
Medscape Medical News

source https://www.medscape.com/viewarticle/997288?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?